Please login to the form below

Not currently logged in
Email:
Password:

lisdexamfetamine dimesylate

This page shows the latest lisdexamfetamine dimesylate news and features for those working in and with pharma, biotech and healthcare.

Shire claims FDA approval for slow-cooked ADHD drug

Shire claims FDA approval for slow-cooked ADHD drug

top ADHD seller Vyvanse (lisdexamfetamine dimesylate) - which pulled in $2bn in sales last year, a rise of 17% and added another $563m in the first quarter.

Latest news

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics